Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Olga Senderova"'
Autor:
Olga Senderova, Ekatarina Yu. Chelysheva, Maria V. Galayko, Alexandr S. Luchinin, Anna G. Turkina, Hunan Julhakyan, L V Gavrilova, Anton Kulikovsky, Valentina Pepeliaeva, Olga V. Lazareva, Sergey Meresiy, Olga Yu. Vinogradova, Galina I. Milutina, Lyudmila B. Avdeeva, Sergey M. Kulikov, Elena B. Dasheeva
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 20:e328-e335
Russia took part in the multicenter population-based study (Europe) and included 6.8% adult patients with newly diagnosed chronic myeloid leukemia (CML). The objective of this study was to analyze the mortality in the Russian cohort of patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2119972ab36a62875942888051d98010
https://doi.org/10.1016/j.clml.2020.02.004
https://doi.org/10.1016/j.clml.2020.02.004
Autor:
Elza Lomaia, E.V. Sokurova, M.A. Mikhalev, M.G. Pozina, Olga Senderova, A.S. Khazieva, A.Yu. Zaritskey, E.B. Zhalsanova, V.V. Ust’yantseva, O.E. Ochirova, Yu.D. Rogovaya, G.P. Dimov, K.B. Trizna, A.Yu. Furtovskaya, A.A. Otmorskaya, O.Yu. Li, NT Siordiya
Publikováno v:
Clinical oncohematology. 13:335-345
Aim. To assess the efficacy of targeted therapy with ruxolitinib in patients with myelofibrosis in real clinical practice in Russia. To determine the prognostic value of spleen reduction in the early stages of ruxolitinib treatment and its effect on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b1d640251bd063bbeb5db1ba8e2f04d7
https://doi.org/10.21320/2500-2139-2020-13-3-335-345
https://doi.org/10.21320/2500-2139-2020-13-3-335-345
Publikováno v:
Kliničeskaâ onkogematologiâ, Vol 12, Iss 3, Pp 297-302 (2019)
Aim. To assess the rate of WT1 gene overexpression and its clinical value in Ph-negative myeloproliferative disorders (MPD). Materials & Methods. The trial included 72 patents with Ph-negative MPD. Among them there were patients with primary myelofib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4479b707f90f49ac772a297d283b7720
https://doaj.org/article/08c71339a67a4db9bb31d030d840b516
https://doaj.org/article/08c71339a67a4db9bb31d030d840b516
Autor:
Olga Senderova, Gysual Safuanova, Andrey Zaritsky, Elza Lomaia, Anton Kulikovsky, Elena Fedorova, Alexandr Korobkin, Marina Kozmina, Lubov Gavrilova, Eva Burnasheva, Elena Volodicheva, Galina Kuchma, Alexander S. Luchinin, Ludmila Napso, Dolgorzhap Dasheeva, Varvara I. Bakhtina, Ekaterina Chelysheva, Anna Lyamkina, Anton Shutilev, Marina Kosinova, Anatoly Golenkov, Vasilisa Skatova, Olga V. Lazareva, Svetlana Volkova, Sergei M. Kulikov, Tatiana Konstantinova, Sergey Voloshin, Vera Yablokova, Tatiana Klitochenko, Anna G. Turkina, Andrew Proidakov, Nataliya Glonina, Andrew Zhuravkov, Tatiana Chagorova, Olga Vinogradova
Publikováno v:
Blood. 138:5035-5035
The results of long-term follow-up of patients (pts) with chronic myeloid leukemia (CML) do not lose their importance. Data from routine clinical practice are of particular interest. The use of 1 st (imatinib, IM) and 2nd generation TKI (2G TKI) led
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a19128c61306200bf830a0b28868e780
https://doi.org/10.1182/blood-2021-151371
https://doi.org/10.1182/blood-2021-151371
Autor:
Sergei M. Kulikov, OYu Vinogradova, Alexander S. Luchinin, L V Gavrilova, MA Galaiko, A Tishchenko, SV Meresii, Olga V. Lazareva, Anna G. Turkina, V M Pepelyaeva, Olga Senderova, GI Milyutina, EYu Chelysheva, L B Avdeeva
Publikováno v:
Kliničeskaâ onkogematologiâ, Vol 10, Iss 2, Pp 65-74 (2017)
Background. Much attention has been paid to molecule-genetic diagnostics of chronic myeloid leukemia (CML) and its treatment using new highly effective methods of therapy. The baseline characteristics of patients at primary CML diagnosis are hardly d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8762dac182869b9afc23f4bef3eabc29
http://bloodjournal.ru/wp-content/uploads/2017/01/9.pdf
http://bloodjournal.ru/wp-content/uploads/2017/01/9.pdf
Autor:
Hunan Julhakyan, Galina I. Milutina, Oleg Shukhov, Lubov Gavrilova, Valentina Pepeliaeva, Olga Vinogradova, Alexander S. Luchinin, Anton Kulikovskiy, Lubov Avdeeva, Maria V. Galayko, Sergey Meresiy, Ekaterina Chelysheva, Olga Senderova, Sergey M. Kulikov, Anna G. Turkina, Elena B. Dasheeva, Olga V. Lazareva
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 19:S298-S299
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b2fbbb5ad4ea2509e119b9f505c82492
https://doi.org/10.1016/j.clml.2019.07.252
https://doi.org/10.1016/j.clml.2019.07.252
Autor:
Galina I. Milutina, Ekaterina Chelysheva, Sergei M. Kulikov, Valentina Pepeliaeva, L B Avdeeva, Anton Kulikovsky, Lubov Gavrilova, Olga Vinogradova, Sergey Meresiy, Dolgorzhap Dasheeva, Olga V. Lazareva, Alexander S. Luchinin, Anna G. Turkina, Olga Senderova
Publikováno v:
Blood. 134:5902-5902
Background: A success of the tyrosine kinase inhibitors (TKI) therapy in patients (pts) with chronic myeloid leukemia (CML) allowed to set a new goal: a treatment-free remission (TFR). A stable and long-lasting deep molecular response (DMR) is requir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a5b90d338bacb27a4741ee02bea1b161
https://doi.org/10.1182/blood-2019-131430
https://doi.org/10.1182/blood-2019-131430
Autor:
Pavel Butylin, Andrey Zaritskey, Natalia Matyuhina, Ekaterina Lisina, Elza Lomaia, Olga Senderova, Nadia Siordia
Publikováno v:
Blood. 128:5499-5499
We analyzed CALR mutations in cohort of patients with ET and PMF. Diagnoses were determined according to the WHO criteria. 33 PMF and 45 ET patients that were negative for JAK2V617F and MPL515L/K mutations have been studied for CALR mutations presenc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::19e0be18fa4a55157f117cf2de75f779
https://doi.org/10.1182/blood.v128.22.5499.5499
https://doi.org/10.1182/blood.v128.22.5499.5499
Autor:
Tatiana Klitochenko, Olga Senderova, Anatoly Golenkov, Anna G. Turkina, Irina Krylova, Lyudmila Napso
Publikováno v:
Blood. 126:5156-5156
Introduction: in the last 10 years the number of tyrosine kinase inhibitors (TKI) used to treat patients with chronic myeloid leukemia (CML) significantly increased. The basic principle of therapy was also changed, now it is aimed at early induction
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::58b42fbc650743b6ded38edabc3ba024
https://doi.org/10.1182/blood.v126.23.5156.5156
https://doi.org/10.1182/blood.v126.23.5156.5156
Autor:
Lubov Gavrilova, Alexander S. Luchinin, Olga Senderova, Vanik A. Ovsepyan, Marya V. Galayko, Sergey V. Meresy, Valentyna M. Pepelyaeva, Sergey M. Kulikov, Galina I. Milutina, Irina A. Titshenko, L B Avdeeva, Olga Vinogradova, Ekaterina Chelysheva, Eduard G. Gendgan, Anna G. Turkina
Publikováno v:
Blood. 120:4431-4431
Abstract 4431 The European Treatment Outcome Study (EUTOS) is register based international investigation started in June 2007. [1] The aim is to study the epidemiology of CML and to gain insight into the ‘real world’ treatment of patients with CM
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2d7cc52958966cd62f42d7247eb16de7
https://doi.org/10.1182/blood.v120.21.4431.4431
https://doi.org/10.1182/blood.v120.21.4431.4431